These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 14722204)

  • 1. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients.
    Feletar M; Brockbank JE; Schentag CT; Lapp V; Gladman DD
    Ann Rheum Dis; 2004 Feb; 63(2):156-61. PubMed ID: 14722204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab monotherapy for refractory psoriasis: preliminary results.
    Cassano N; Loconsole F; Amoruso A; Coviello C; Filieri M; Filotico R; Del Vecchio S; Vena GA
    Int J Immunopathol Pharmacol; 2004; 17(3):373-80. PubMed ID: 15461871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab.
    Cauza E; Spak M; Cauza K; Hanusch-Enserer U; Dunky A; Wagner E
    Rheumatol Int; 2002 Nov; 22(6):227-32. PubMed ID: 12426660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
    Antoni C; Krueger GG; de Vlam K; Birbara C; Beutler A; Guzzo C; Zhou B; Dooley LT; Kavanaugh A;
    Ann Rheum Dis; 2005 Aug; 64(8):1150-7. PubMed ID: 15677701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study.
    Baranauskaite A; Raffayová H; Kungurov NV; Kubanova A; Venalis A; Helmle L; Srinivasan S; Nasonov E; Vastesaeger N;
    Ann Rheum Dis; 2012 Apr; 71(4):541-8. PubMed ID: 21994233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab for psoriasis and psoriatic arthritis.
    Antoni C; Manger B
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S122-5. PubMed ID: 12463461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study.
    Goedkoop AY; Kraan MC; Picavet DI; de Rie MA; Teunissen MB; Bos JD; Tak PP
    Arthritis Res Ther; 2004; 6(4):R326-34. PubMed ID: 15225368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT).
    Antoni CE; Kavanaugh A; van der Heijde D; Beutler A; Keenan G; Zhou B; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman DD; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen JS
    J Rheumatol; 2008 May; 35(5):869-76. PubMed ID: 18381786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
    Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
    Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
    Torii H; Nakagawa H;
    J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicentre study on high-frequency ultrasound evaluation of the skin and joints in patients with psoriatic arthritis treated with infliximab.
    De Agustín JJ; Moragues C; De Miguel E; Möller I; Acebes C; Naredo E; Uson J; Rejon E; Mayordomo L; Garrido J
    Clin Exp Rheumatol; 2012; 30(6):879-85. PubMed ID: 23020866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
    Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
    Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
    Kavanaugh A; McInnes I; Mease P; Krueger GG; Gladman D; Gomez-Reino J; Papp K; Zrubek J; Mudivarthy S; Mack M; Visvanathan S; Beutler A
    Arthritis Rheum; 2009 Apr; 60(4):976-86. PubMed ID: 19333944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study.
    Gladman DD; ; Sampalis JS; Illouz O; Guérette B
    J Rheumatol; 2010 Sep; 37(9):1898-906. PubMed ID: 20595284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.
    Kavanaugh A; Krueger GG; Beutler A; Guzzo C; Zhou B; Dooley LT; Mease PJ; Gladman DD; de Vlam K; Geusens PP; Birbara C; Halter DG; Antoni C;
    Ann Rheum Dis; 2007 Apr; 66(4):498-505. PubMed ID: 17114188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate.
    Gratacós J; Casado E; Real J; Torre-Alonso JC
    Ann Rheum Dis; 2007 Apr; 66(4):493-7. PubMed ID: 17179176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study.
    Voulgari PV; Venetsanopoulou AI; Exarchou SA; Alamanos Y; Tsifetaki N; Drosos AA
    Semin Arthritis Rheum; 2008 Apr; 37(5):293-8. PubMed ID: 17888499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Golimumab for the treatment of psoriatic arthritis.
    Yang H; Epstein D; Bojke L; Craig D; Light K; Bruce I; Sculpher M; Woolacott N
    Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine profiles during infliximab monotherapy in psoriatic arthritis.
    Mastroianni A; Minutilli E; Mussi A; Bordignon V; Trento E; D'Agosto G; Cordiali-Fei P; Berardesca E
    Br J Dermatol; 2005 Sep; 153(3):531-6. PubMed ID: 16120138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.